Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

61. Telepsychiatry intervention is better for ADHD symptoms than usual treatment augmented by telemedicine consultation. (Abstract)

; carol.rockhill@seattlechildrens.org. eng Journal Article Comment 2015 10 01 England Evid Based Ment Health 100883413 1362-0347 IM J Am Acad Child Adolesc Psychiatry. 2015 Apr;54(4):263-74 25791143 Attention Deficit Disorder with Hyperactivity Humans Referral and Consultation Telemedicine PUBLIC HEALTH 2015 06 22 2015 09 15 2015 10 3 6 0 2015 10 3 6 0 2016 8 25 6 0 ppublish 26429338 eb-2015-102151 10.1136/eb-2015-102151 (...) Telepsychiatry intervention is better for ADHD symptoms than usual treatment augmented by telemedicine consultation. 26429338 2016 08 24 2018 12 02 1468-960X 18 4 2015 Nov Evidence-based mental health Evid Based Ment Health Telepsychiatry intervention is better for ADHD symptoms than usual treatment augmented by telemedicine consultation. e9 10.1136/eb-2015-102151 Rockhill Carol C Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA

2016 Evidence-Based Mental Health Controlled trial quality: uncertain

62. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. Full Text available with Trip Pro

Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study.  To determine whether treatment with methylphenidate in children and young people with attention-deficit/hyperactivity disorder (ADHD) was associated with cardiovascular events. Self controlled case series analysis. Nationwide health insurance database, 1 January 2008 to 31 December 2011, in South Korea. 1224 patients aged (...) in the early risk periods between eight and 56 days after the start of treatment with methylphenidate. No significant increased risk was observed for hypertension, ischemic stroke, or heart failure. The relative risk of myocardial infarction and arrhythmias is increased in the early period after the start of methylphenidate treatment for ADHD in children and young people. Though the absolute risk is likely to be low, the risk-benefit balance of methylphenidate should be carefully considered, particularly

2016 BMJ

63. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review. (Abstract)

Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review. Although attention-deficit/hyperactivity disorder (ADHD) is highly prevalent in adolescents and often persists into adulthood, most studies about treatment were performed in children. Less is known about ADHD treatment in adolescents.To review the evidence for pharmacological and psychosocial treatment of ADHD in adolescents.The databases of CINAHL Plus, MEDLINE, PsycINFO, ERIC, and the Cochrane Database (...) Scale (score range, 0 [least symptomatic] to 54 [most symptomatic]), both stimulant and nonstimulant medications led to clinically significant reductions of 14.93 to 24.60 absolute points. The psychosocial treatments combining behavioral, cognitive behavioral, and skills training techniques demonstrated small- to medium-sized improvements (range for mean SD difference in Cohen d, 0.30-0.69) for parent-rated ADHD symptoms, co-occurring emotional or behavioral symptoms, and interpersonal functioning

2016 JAMA

64. Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release

in March 2016. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date information. Summary Guanfacine prolonged-release (Intuniv) is a non-stimulant treatment for children and young people with attention deficit hyperactivity disorder (ADHD). In 3 short-term, randomised controlled trials (RCTs) it was more effective than placebo at improving ADHD symptoms, although a beneficial effect on social functioning (...) February 2016). Atomoxetine 4 mg/ml oral solution (Strattera) costs £23.33–£233.33 for 28 days treatment at a dose of 10–100 mg daily (excluding VAT; Drug T ariff, February 2016). Introduction and current guidance Attention deficit hyperactivity disorder (ADHD) is a heterogeneous behavioural syndrome characterised by the core symptoms of hyperactivity, impulsivity and inattention. The NICE guideline on ADHD (currently being updated, publication expected January 2018) covers diagnosing and managing ADHD

2016 National Institute for Health and Clinical Excellence - Advice

65. Pharmacologic Management of Patients with ADHD: Review of Guidelines

. There is limited evidence to support the efficacy or safety of combination therapy for ADHD comprising stimulant and non-stimulant drugs in patients with inadequate clinical response to monotherapy. Tags attention deficit disorder with hyperactivity, attention deficit and disruptive behavior disorders, mental health, ADHD, Attention deficit Files Rapid Response Summary with Critical Appraisal Published : March 18, 2016 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get (...) Pharmacologic Management of Patients with ADHD: Review of Guidelines Pharmacologic Management of Patients With ADHD: Review of Guidelines | CADTH.ca Find the information you need Pharmacologic Management of Patients With ADHD: Review of Guidelines Pharmacologic Management of Patients With ADHD: Review of Guidelines Published on: March 18, 2016 Project Number: RC0759-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

66. High-dose Stimulants for Attention Deficit Hyperactivity Disorder: A Review of the Clinical Effectiveness, Safety and Guidelines

: A Review of the Clinical Effectiveness, Safety, and Guidelines Published on: March 3, 2016 Project Number: RC0754-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the effectiveness and safety of high dose stimulants in children and adolescents (six to 18 years) with attention-deficit/hyperactivity disorder (ADHD)? What is the comparative effectiveness and safety of high dose stimulants in adults (> 18 years) with ADHD? What (...) in adolescents with ADHD was identified; high doses of study medication were more effective than placebo at addressing symptoms, but had uncertain effects on quality of life measures. Three non-randomized studies regarding adverse events for adolescents and adults using high doses of methylphenidate were identified; these doses were generally well tolerated by patients. Tags amphetamine, amphetamines, attention deficit disorder with hyperactivity, central nervous system stimulants, dexamfetamine, dexedrine

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

67. Combination Therapy for Attention Deficit Hyperactivity Disorder: A Review of the Clinical Effectiveness

patients with ADHD. Tags amphetamine, attention deficit disorder with hyperactivity, delayed-action preparations, dexamfetamine, dexedrine, dexmethylphenidate, dextroamphetamine, focalin, learning disorders, methylphenidate, ritalin, learning disorder, AD/HD, ADD, Adderall, Attention deficit, Concerta, Long acting, Slow acting, atomoxetine, controlled delivery, controlled release, delayed release, extended release, immediate release, lisdexamfetamine dimesylate, short acting, sustained release, vyvanse (...) Combination Therapy for Attention Deficit Hyperactivity Disorder: A Review of the Clinical Effectiveness Combination Therapy for Attention-Deficit/Hyperactivity Disorder: A Review of the Clinical Effectiveness | CADTH.ca Find the information you need Combination Therapy for Attention-Deficit/Hyperactivity Disorder: A Review of the Clinical Effectiveness Combination Therapy for Attention-Deficit/Hyperactivity Disorder: A Review of the Clinical Effectiveness Published on: February 23, 2016

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

68. The challenges of implementing ADHD clinical guidelines and research best evidence in routine clinical care settings: Delphi survey and mixed-methods study Full Text available with Trip Pro

The challenges of implementing ADHD clinical guidelines and research best evidence in routine clinical care settings: Delphi survey and mixed-methods study The landmark US Multimodal Treatment of ADHD (MTA) study established the benefits of individualised medication titration and optimisation strategies to improve short- to medium-term outcomes in attention-deficit hyperactivity disorder (ADHD). This individualised medication management approach was subsequently incorporated into the National (...) Institute for Health and Care Excellence (NICE) ADHD Clinical Guidelines (NICE CG78). However, little is known about clinicians' attitudes towards implementing these medication management strategies for ADHD in routine care.To examine National Health Service (NHS) healthcare professionals' consensus on ADHD medication management strategies.Using the Delphi method, we examined perceptions on the importance and feasibility of implementing 103 ADHD treatment statements from sources including the UK NICE

2016 BJPsych open

69. Outcomes: Clarifying the nuances in ADHD and health outcomes: a case of overweight and obesity

Statistics from Altmetric.com ABSTRACT FROM: Cortese S, Moreira-Maia CR, St Fleur D, et al. Association between ADHD and obesity: a systematic review and meta-analysis. Am J Psychiatry 2016;173:34–43. What is already known on this topic? Children with attention-deficit/hyperactivity disorder (ADHD) are at elevated risk of a host of negative life outcomes, including both psychiatric and health complications. 1 While the psychiatric complications are well established, the question of physical health (...) Outcomes: Clarifying the nuances in ADHD and health outcomes: a case of overweight and obesity Clarifying the nuances in ADHD and health outcomes: a case of overweight and obesity | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers

2016 Evidence-Based Mental Health

70. Psychoeducation for adults with Attention Deficit Hyperactivity Disorder (ADHD)

Psychoeducation for adults with Attention Deficit Hyperactivity Disorder (ADHD) Psychoeducation for adults with Attention Deficit Hyperactivity Disorder (ADHD) - NIPH Selected items added to basket Close Search for: Søk Meny Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle Close Health in Norway Close Quality & Knowledge Close Research & Access to data Close About NIPH Close Psychoeducation for adults with Attention Deficit Hyperactivity Disorder (ADHD (...) ) Have you found an error? Order Download: Key message The Norwegian Institute of Public Health, Knowledge Centre was commissioned by “Bestillerforum RHF” to undertake a rapid review of research on Psychoeducation for adults with Attention Deficit Hyperactivity Disorder (ADHD). Methods We conducted a systematic search in nine medical, social science and health-related databases to identify relevant research publications about adults with ADHD and psychoeducative treatment. The search was conducted

2016 Norwegian Institute of Public Health

71. Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Full Text available with Trip Pro

Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylphenidate for ADHD in children and adolescents: throwing the baby out with the bathwater Article Text Perspective Methylphenidate for ADHD in children and adolescents: throwing the baby out

2016 Evidence-Based Mental Health

72. Evidence on methylphenidate in children and adolescents with ADHD is in fact of ?very low quality? Full Text available with Trip Pro

Evidence on methylphenidate in children and adolescents with ADHD is in fact of ?very low quality? Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’ | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’ Article Text Perspective Evidence on methylphenidate in children and adolescents with ADHD

2016 Evidence-Based Mental Health

73. ADHD in Children and Adolescents

of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents was developed by the American Academy of Pediatrics (AAP) and endorsed by the American Academy of Family Physicians (AAFP). Key Recommendations Any child 4 through 18 years of age who presents with academic or behavioral problems and symptoms of inattention, hyperactivity, or impulsivity should be evaluated for ADHD. The diagnosis of ADHD should be based on the criteria from the Diagnostic and Statistical Manual of Mental Disorders (...) medications for ADHD and may be treated with behavioral therapy. Medication doses should be titrated to achieve maximum benefit with minimum adverse effects. Access the article with full recommendation for more information on ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. * Please note that the AAP has also developed a Process of Care Supplemental Appendix document, available on the AAP website, which

2016 American Academy of Family Physicians

74. Practice advisory: the utility of eeg theta/beta power ratio in adhd diagnosis

. Kernberg OF , Yeomans FE . Borderline personality disorder, bipolar disorder, depression, attention deficit/hyperactivity disorder, and narcissistic personality disorder: practical differential diagnosis . 16. Connor DF , Doerfler LA . ADHD with comorbid oppositional defiant disorder or conduct disorder: discrete or nondistinct disruptive behavior disorders? 17. American Academy of Pediatrics . Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity (...) .), University of California at Los Angeles. Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis David Gloss , Jay K. Varma , Tamara Pringsheim , Marc R. Nuwer Neurology Nov 2016, 87 (22) 2375-2379; DOI: 10.1212/WNL.0000000000003265 Citation Manager Formats Make Comment See Comments Downloads 2753 Share Abstract Objective: To evaluate the evidence for EEG theta/beta power ratio for diagnosing, or helping to diagnose, attention-deficit/hyperactivity disorder (ADHD). Methods: We

2016 American Academy of Neurology

75. ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines

or mood changes was identified. One evidence-based guideline suggested switching to atomoxetine in this clinical situation, however, the evidence for this recommendation was limited. Tags attention deficit disorder with hyperactivity, attention deficit and disruptive behavior disorders, drug substitution, learning disorders, learning disorder, Replacement, substitution Files Rapid Response Summary with Critical Appraisal Published : September 15, 2015 Related Content Follow us: © 2019 Canadian Agency (...) ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

76. Dosage Delivery of ADHD Medications for Patients with Swallowing Difficulties: Guidelines

Report Type: Summary of Abstracts Result type: Report Question What is the clinical evidence regarding methods of dosage delivery of attention deficit hyperactivity disorder (ADHD) medications to patients with swallowing difficulties? What are the evidence-based guidelines regarding method of dosage delivery of ADHD medications to patients with swallowing difficulties? Key Message One evidence-based guideline was identified regarding methods of dosage delivery of ADHD medications to patients (...) with swallowing difficulties. Tags attention deficit disorder with hyperactivity, deglutition disorders, mental health, tablets, ADHD, amphetamine mixed salts, controlled delivery, drug dissolution, drug liberation, pellet technology Files Rapid Response Summary of Abstracts Published : September 3, 2015 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter:

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

77. Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder

Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder | CADTH.ca Find the information you need Duration of Dosage Effect for Methylphenidate SR and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder Duration of Dosage Effect for Methylphenidate SR (...) and Dextroamphetamine SR for Patients with Attention Deficit Hyperactivity Disorder Published on: September 2, 2015 Project Number: RB0904-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical evidence for the duration of dosage effect for methylphenidate SR and dextroamphetamine SR for patients with attention deficit hyperactivity disorder? Key Message One systematic review, two randomized controlled trials, and two non-randomized studies were

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

78. Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD) delivered in school settings: systematic reviews of quantitative and qualitative research Full Text available with Trip Pro

Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD) delivered in school settings: systematic reviews of quantitative and qualitative research Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD)delivered in school settings: systematic reviews of quantitative and qualitative research Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page

2015 NIHR HTA programme

79. Medical augmentation of labor and the risk of ADHD in offspring: a population-based study Full Text available with Trip Pro

Medical augmentation of labor and the risk of ADHD in offspring: a population-based study Oxytocin for labor augmentation is widely used in obstetric care in Western countries. Two recent, smaller studies found opposing results regarding the association between prenatal exposure to oxytocin for labor augmentation and attention-deficit/hyperactivity disorder (ADHD). In Denmark, oxytocin is the medication used for nearly all medical augmentations of labor, and we examined the association between (...) medical augmentation of labor and ADHD in a large cohort study based on national register data.All singletons born after spontaneous onset of labor in Denmark between 2000 and 2008 (N = 546 146) were included in the study. Data from the Danish Medical Birth Registry on medical augmentation of labor (yes/no) were used to identify exposed children. ADHD was defined based on the diagnostic codes of International Classification of Diseases, 10th Revision, for hyperkinetic disorder and information

2015 EvidenceUpdates

80. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. (Abstract)

Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Attention deficit hyperactivity disorder (ADHD) is a common mental disorder associated with factors that are likely to increase mortality, such as oppositional defiant disorder or conduct disorder, criminality, accidents, and substance misuse. However, whether ADHD itself is associated with increased mortality remains unknown. We aimed to assess ADHD-related mortality (...) in a large cohort of Danish individuals.By use of the Danish national registers, we followed up 1·92 million individuals, including 32,061 with ADHD, from their first birthday through to 2013. We estimated mortality rate ratios (MRRs), adjusted for calendar year, age, sex, family history of psychiatric disorders, maternal and paternal age, and parental educational and employment status, by Poisson regression, to compare individuals with and without ADHD.During follow-up (24·9 million person-years), 5580

2015 Lancet